Investing.com — Shares in jumped as much as 15% on Thursday, their highest level since October 2025, a day after the German pharmaceutical packaging maker raised its full-year guidance and reported preliminary third-quarter results that beat market expectations.
Schott Pharma said preliminary third-quarter figures showed constant-currency revenue growth of approximately 8% and an EBITDA margin of approximately 27%, exceeding market expectations of 3.5% growth and a 27.5% margin, according to the Vara Consensus as of July 6.
For fiscal year 2026, the company raised its constant-currency revenue growth guidance to 5%-6%, from a prior range of 2%-5%, and its EBITDA margin target to 27%-28%, from approximately 27%.
Both revised targets exceed current market expectations of 3.2% revenue growth and a 27.2% EBITDA margin, based on the same consensus source.
The company attributed the improved outlook to strong business performance, fourth-quarter expectations, and a settlement with a key glass syringe customer whose dispute had triggered a profit warning in December 2025.
The agreement carries “both revenue-related and compensation components, which will have an impact on future periods,” Schott Pharma said.
RBC Capital Markets upgraded Schott Pharma to “outperform” from “sector perform” on Wednesday, raising its price target to €21 from €18. The brokerage said it had sought resolution of the glass syringe dispute and “tangible evidence of an inflection” before upgrading, and that the release “ticks those boxes.”
RBC said the preliminary figures implied a third-quarter EBITDA beat of 2% versus consensus, a 9% EBITDA beat for the fourth quarter, and a 2.3% EBITDA beat for the full year. The brokerage raised its 2026 forecasts by 3% on revenue and 6% on EBITDA, and its 2027 forecasts by 2% and 3%, respectively.
Deutsche Bank also raised its price target on the stock, to a range of €22 to €23 from an unspecified prior level, maintaining a “buy” rating.
“Schott Pharma has pre-released stronger-than-expected Q3 results, with preliminary figures pointing to 8% organic sales growth and a 27% EBITDA margin, coming in 4% and 2% ahead of consensus, respectively,” Deutsche Bank analyst Falko Friedrichs said in a note.
“While we recently upgraded the stock to Buy on the expectation of accelerating growth we are positively surprised by the magnitude of this beat and guidance raise and believe it serves as a major catalyst for the shares.”